Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00594646 · ClinicalTrials.gov registry record · Phase 4
HIV Non Occupational Post-Exposure Prophylaxis (PEP)
A Phase 4 study, sponsored by Fenway Community Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00594646 is a Phase 4 study that has completed, run by Fenway Community Health. The registered enrollment target is 100 participants.
The verdict
NCT00594646, a Phase 4 study, has completed, sponsored by Fenway Community Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
Interventions
- DRUG TRUVADA + Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00594646
The ClinicalTrials.gov registry entry for NCT00594646 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fenway Community Health, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRUVADA + Raltegravir is the first listed.
NCT00594646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00594646 about?
NCT00594646 is a clinical study titled "HIV Non Occupational Post-Exposure Prophylaxis (PEP)". This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.
What is the current status of trial NCT00594646?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2008-02. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00594646?
The interventions under investigation include: TRUVADA + Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00594646?
This trial is sponsored by Fenway Community Health, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.